Table 1 Baseline Characteristics and Demographics.
ART-naïve patients (n = 175) | Pretreated, but PI-naïve patients (n = 109) | |
|---|---|---|
Male (n) | 86% (n = 150) | 79% (n = 86) |
Age in years, Median (IQR) | 39 (33; 46) | 41 (37; 50) |
Height in cm, Median, (IQR) | 176 (172; 183) | 178 (170; 182) |
Weight in kg, Median (IQR) | 72 (65; 79) | 72 (65; 80) |
Hepatitis B coinfection | 5% (n = 9) | 2% (n = 2) |
Hepatitis C coinfection | 12% (n = 21) | 10% (n = 11) |
Infection mode | ||
MSM | 61% | 59% |
Heterosexual | 19% | 17% |
IVDU | 6% | 6% |
Not specified | 14% | 18% |
Race | ||
Caucasian | 85% | 78% |
African | 8% | 11% |
Asian | 3% | 5% |
Not specified | 4% | 6% |
CDC stage | ||
A | 38% | 29% |
B | 33% | 51% |
C | 27% | 17% |
Not specified | 2% | 3% |
Time since first diagnosis in years, Median (IQR) | 1 (0; 4) | 9 (5; 13) |
Time since first ART in months, Median (IQR) | - | 79 (37; 104) |
Number of previous regimen, Median (IQR) | - | 3 (2; 4) |
Treatment interruption before start of new regimen | - | 28% (n = 30) |
Duration of treatment interruption in months, Median (IQR) | - | 24 (6; 40) |
HIV RNA (copies/mL), Median (IQR) | 117,000 | 3,433 |
(36,548; 336,000) | (92; 34,384) | |
CD4-count (cells/mm 3 ) Median (IQR) | 196 (82; 284) | 319 (204; 478) |